FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer

Дата публикации: 10-07-2026 03:07:39

RAHWAY, N.J.--(BUSINESS WIRE) July 10, 2026 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) and Keytruda Qlex...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	FDA Approves Keytruda (pembrolizumab) and Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)	0	17.02	25-06-2026
2	U.S. FDA Approves Padcev plus Keytruda or Keytruda Qlex as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility	0	13.8	10-07-2026
3	FDA Grants Traditional Approval to Retevmo (selpercatinib) for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors	0	8.58	14-07-2026
4	FDA Grants Accelerated Approval to Zenbexus (iberdomide) in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone for the Treatment of Multiple Myeloma	0	11.39	13-08-2026
5	U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer	0	20.66	24-06-2026
6	FDA Approves Jideytro (zidesamtinib) for Previously Treated ROS1-Positive Non-Small Cell Lung Cancer	0	16.54	22-07-2026
7	FDA Approves Pluvicto for PSMA+ Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	0	17.15	31-07-2026
8	FDA Approves Revtorpyk (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer	0	18.09	14-07-2026
9	Celltrion Becomes First to Acquire U.S. Interchangeability Status for Truxima	0	9.51	01-07-2026
10	FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer	5	5	08-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 11.85. Источник: www.drugs.com.